CDRH third-party program
This article was originally published in The Gray Sheet
Executive Summary
Comments are due by Sept. 1 on the agency's proposal to expand its third-party program to 460 Class II devices for which device-specific guidance does not yet exist (1"The Gray Sheet" June 19, p. 5)
You may also be interested in...
FDA Pilots Expansion Of Third-Party Review To Devices Without Guidance
Only six of the twelve "accredited persons" have reviewed three or more 510(k) applications under the current third-party program, a requirement for participation in FDA's expanded third-party pilot.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.